EYEN - Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet® | Benzinga
In rigorous testing, the Optejet remained contaminant-free when subjected to a microbial load that exceeds typical environmental conditions
Presentation to be made at the American Academy of Optometry's "Academy 2023 New Orleans" Annual Meeting
NEW YORK, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP13007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced Optejet® device with late-stage product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that it will deliver a presentation on the microbial integrity of its Optejet dispensing device at the American Academy of Optometry's "Academy 2023 New Orleans" Annual Meeting, which is being held October 11-14, 2023.
"Recent studies of both preserved and preservative-free multi-use eye drops have shown contamination rates as high as 94%, suggesting that there is an urgent need for a next-generation topical ophthalmic drug dispensing device that can administer medication without preservatives or contaminants, both of which can be harmful to the eye," stated Michael Rowe, chief executive officer of Eyenovia. "This study successfully demonstrates the Optejet's ability to maintain product sterility even when exposed to a microbial load that exceeds typical environmental conditions, supporting the potential for the Optejet to be used to deliver preservative-free medications, which would confer significant long-term benefits to patients."
| Presentation details: |
| Title: |
| Demonstration of Microbial Integrity for a ... |